The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Published Online:https://doi.org/10.1176/ps.45.6.556

The high proportion of persons presenting for treatment of psychiatric disorders who also have comorbid substance use problems severely challenges the capacity of mental health care programs to plan for patients' needs. One of the problems encountered in anticipating the treatment needs of these patients is the wide beterogeneity of their comorbidity, that is, the broadly varying types, severity, and time courses of psychiatric and substance disorders. This paper describes and evaluates a relatively simple conceptual framework for delineating the beterogencity of patients who are dually diagnosed. Methods: A typology of subgroups of patients was defined a priori based on whether patients are singly or dually diagnosed and whether their disorders are current or past. Patients admitted to three treatment facilities in an inner-city catchment area were assigned to one of the subgroups based on administration of the Structured Clinical interview for DSM-III-R-Patient Version (SCID-P). The subgroups were compared on clinical diagnoses and service needs as measured by the SCID-P and the Addiction Severity index. Results: A total of 461 patients were assigned to four mutually exclusive dual diagnosis subgroups-patients with current definite dual diagnoses, current possible dual diagnoses, current substance-induced organic mental disorder, and past definite dual diagnoses—and the two comparison groups. The subgroups differed significantly from each other and from two single-diagnosis comparison groups on axis i diagnoses, types of substance use disorders, and current problem areas. Conclusions: The framework developed has potential utility for distinguishing subgroups of dually diagnosed patients relevant for service planning.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.